Search / Trial NCT00002533

Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
Launched by UNIVERSITY OF MIAMI · Sep 17, 2003

Trial Information

Current as of July 21, 2025

Completed

Keywords

Untreated Metastatic Squamous Neck Cancer With Occult Primary Recurrent Metastatic Squamous Neck Cancer With Occult Primary Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Oral Complications Stage I Squamous Cell Carcinoma Of The Lip And Oral Cavity Stage I Basal Cell Carcinoma Of The Lip Stage I Verrucous Carcinoma Of The Oral Cavity Stage I Mucoepidermoid Carcinoma Of The Oral Cavity Stage I Adenoid Cystic Carcinoma Of The Oral Cavity Stage Ii Squamous Cell Carcinoma Of The Lip And Oral Cavity Stage Ii Basal Cell Carcinoma Of The Lip Stage Ii Verrucous Carcinoma Of The Oral Cavity Stage Ii Mucoepidermoid Carcinoma Of The Oral Cavity Stage Ii Adenoid Cystic Carcinoma Of The Oral Cavity Stage Iii Squamous Cell Carcinoma Of The Lip And Oral Cavity Stage Iii Basal Cell Carcinoma Of The Lip Stage Iii Verrucous Carcinoma Of The Oral Cavity Stage Iii Mucoepidermoid Carcinoma Of The Oral Cavity Stage Iii Adenoid Cystic Carcinoma Of The Oral Cavity Stage Iv Squamous Cell Carcinoma Of The Lip And Oral Cavity Stage Iv Basal Cell Carcinoma Of The Lip Stage Iv Verrucous Carcinoma Of The Oral Cavity Stage Iv Mucoepidermoid Carcinoma Of The Oral Cavity Stage Iv Adenoid Cystic Carcinoma Of The Oral Cavity Recurrent Squamous Cell Carcinoma Of The Lip And Oral Cavity Recurrent Basal Cell Carcinoma Of The Lip Recurrent Verrucous Carcinoma Of The Oral Cavity Recurrent Mucoepidermoid Carcinoma Of The Oral Cavity Recurrent Adenoid Cystic Carcinoma Of The Oral Cavity Stage I Squamous Cell Carcinoma Of The Oropharynx Stage I Lymphoepithelioma Of The Oropharynx Stage Ii Squamous Cell Carcinoma Of The Oropharynx Stage Ii Lymphoepithelioma Of The Oropharynx Stage Iii Squamous Cell Carcinoma Of The Oropharynx Stage Iii Lymphoepithelioma Of The Oropharynx Stage Iv Squamous Cell Carcinoma Of The Oropharynx Stage Iv Lymphoepithelioma Of The Oropharynx Recurrent Squamous Cell Carcinoma Of The Oropharynx Recurrent Lymphoepithelioma Of The Oropharynx Stage I Squamous Cell Carcinoma Of The Nasopharynx Stage I Lymphoepithelioma Of The Nasopharynx Stage Ii Squamous Cell Carcinoma Of The Nasopharynx Stage Ii Lymphoepithelioma Of The Nasopharynx Stage Iii Squamous Cell Carcinoma Of The Nasopharynx Stage Iii Lymphoepithelioma Of The Nasopharynx Stage Iv Squamous Cell Carcinoma Of The Nasopharynx Stage Iv Lymphoepithelioma Of The Nasopharynx Recurrent Squamous Cell Carcinoma Of The Nasopharynx Recurrent Lymphoepithelioma Of The Nasopharynx Stage I Squamous Cell Carcinoma Of The Hypopharynx Stage Ii Squamous Cell Carcinoma Of The Hypopharynx Stage Iii Squamous Cell Carcinoma Of The Hypopharynx Stage Iv Squamous Cell Carcinoma Of The Hypopharynx Recurrent Squamous Cell Carcinoma Of The Hypopharynx Stage I Squamous Cell Carcinoma Of The Larynx Stage I Verrucous Carcinoma Of The Larynx Stage Ii Squamous Cell Carcinoma Of The Larynx Stage Ii Verrucous Carcinoma Of The Larynx Stage Iii Squamous Cell Carcinoma Of The Larynx Stage Iii Verrucous Carcinoma Of The Larynx Stage Iv Squamous Cell Carcinoma Of The Larynx Stage Iv Verrucous Carcinoma Of The Larynx Recurrent Squamous Cell Carcinoma Of The Larynx Recurrent Verrucous Carcinoma Of The Larynx Stage I Squamous Cell Carcinoma Of The Paranasal Sinus And Nasal Cavity Stage I Inverted Papilloma Of The Paranasal Sinus And Nasal Cavity Stage I Midline Lethal Granuloma Of The Paranasal Sinus And Nasal Cavity Stage I Esthesioneuroblastoma Of The Paranasal Sinus And Nasal Cavity Stage Ii Squamous Cell Carcinoma Of The Paranasal Sinus And Nasal Cavity Stage Ii Inverted Papilloma Of The Paranasal Sinus And Nasal Cavity Stage Ii Midline Lethal Granuloma Of The Paranasal Sinus And Nasal Cavity Stage Ii Esthesioneuroblastoma Of The Paranasal Sinus And Nasal Cavity Stage Iii Squamous Cell Carcinoma Of The Paranasal Sinus And Nasal Cavity Stage Iii Inverted Papilloma Of The Paranasal Sinus And Nasal Cavity Stage Iii Midline Lethal Granuloma Of The Paranasal Sinus And Nasal Cavity Stage Iii Esthesioneuroblastoma Of The Paranasal Sinus And Nasal Cavity Stage Iv Squamous Cell Carcinoma Of The Paranasal Sinus And Nasal Cavity Stage Iv Inverted Papilloma Of The Paranasal Sinus And Nasal Cavity Stage Iv Midline Lethal Granuloma Of The Paranasal Sinus And Nasal Cavity Stage Iv Esthesioneuroblastoma Of The Paranasal Sinus And Nasal Cavity Recurrent Squamous Cell Carcinoma Of The Paranasal Sinus And Nasal Cavity Recurrent Inverted Papilloma Of The Paranasal Sinus And Nasal Cavity Recurrent Midline Lethal Granuloma Of The Paranasal Sinus And Nasal Cavity Recurrent Esthesioneuroblastoma Of The Paranasal Sinus And Nasal Cavity Infection

ClinConnect Summary

OBJECTIVES:

* Determine the effect of prophylactic antifungal therapy with fluconazole on the incidence and severity of radiation-associated mucositis/thrush in patients with head and neck cancer undergoing definitive radiotherapy.

OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients undergo standard hyperfractionated radiotherapy 5 days a week for 5-5.6 weeks. Patients receive oral fluconazole on days 1-4 and 28-31 of radiotherapy.
* Arm II: Patients undergo radiotherapy as in arm I. Patients who develop a microbiologically proven fung...

Gender

ALL

Eligibility criteria

DISEASE CHARACTERISTICS:
• Histologically proven head and neck cancer undergoing definitive radiotherapy
PATIENT CHARACTERISTICS:
Age:
• Over 21
Performance status:
• Karnofsky 70-100%
Hematopoietic:
• Not specified
Hepatic:
• SGOT and SGPT less than 2 times normal
• Alkaline phosphatase less than 2 times normal
Renal:
• Not specified
Other:
• No history of hypersensitivity to fluconazole
• HIV negative
PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• Not specified
• Endocrine therapy
• Not specified
• Radiotherapy
• Not specified
• Surgery
• Not specified
• Other
• At least 2 months since prior antifungal agents
• Not currently receiving phenytoin, hydrochlorothiazide, or warfarin
• If these medications are initiated during study therapy, medication serum levels and electrolytes are monitored for possibility of drug interaction

About University Of Miami

The University of Miami, a leading academic institution, is dedicated to advancing medical research and improving patient care through innovative clinical trials. With a commitment to excellence in education and research, the university fosters collaboration among multidisciplinary teams to explore new therapies and treatment modalities. Its extensive clinical programs are supported by state-of-the-art facilities and a diverse patient population, enabling the exploration of cutting-edge solutions to complex health challenges. The University of Miami is poised to contribute significantly to the field of medicine through its rigorous scientific inquiry and a steadfast commitment to ethical research practices.

Locations

Miami, Florida, United States

Patients applied

0 patients applied

Trial Officials

Arnold M. Markoe, MD, ScD

Study Chair

University of Miami Sylvester Comprehensive Cancer Center

Timeline

First submit

November 01, 1999

Trial launched

February 01, 1993

Trial updated

December 14, 2016

Estimated completion

Not reported

Similar Trials

Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Launched by UNIVERSITY OF MIAMI · Sep 17, 2003

Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
Launched by UNIVERSITY OF MIAMI · Sep 17, 2003